MOLDTKPACBSEMold-Tek Packaging LtdMediumNeutral
Announced Fri, 15 May · 18:06 IST

Transcript of Earnings Conference Call held on May 11, 2026

Mgmt Guided Margin ImprovementOrder Pipeline DisclosedCfo Debt Reduction RoadmapAnalyst Day Multiyear TargetsInvestor Communications View source PDF

MOLDTKPAC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.8%1-day move
₹702.60
prior close
₹703.20
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.8-2.0-2.4-3.1-2.8-4.0-2.2-2.5-0.0-2.1-1.4-2.9-0.2
Up moveDown movePending
AI summary

Mold-Tek Packaging reported strong Q4 and full-year FY26 results with 13.4% sales growth. The consolidation of Hyderabad units (5 into 2) improved efficiencies and EBITDA margins to 40.7% from 37.6% last year. Pharma segment surged 200%+ to INR34.3 crores, while Paint delivered double-digit growth with Asian Paints recovering 17% in Q4. However, Lubricants declined sharply due to loss of BPCL (INR14-15 crores). Management guided FY27 revenue growth of 13-15% (value) and 10-13% (volume), targeting INR1,000+ crores sales and EBITDA of INR210 crores (up ~21%). Pharma is guided at INR50-55 crores. Capex to reduce to INR80-85 crores in FY27 from INR120 crores this year, funded entirely from internal accruals with no additional debt required. Capacity to reach ~67,000-68,000 tons by FY27 end.

Likely market impact

The company's multi-segment growth strategy and operational consolidation are yielding margin improvements. Management's clear guidance of 20%+ EBITDA growth and declining capex requirements signal improving cash generation, which could support debt reduction and shareholder returns. Pharma expansion and new client additions in Food/FMCG provide multi-year visibility.